Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Melatonin has been known to be a chemopreventive agent since its levels inversely correlate with the risk of developing cancer. We have recently shown that melatonin induces p38-dependent phosphorylation of both p53 and histone H2AX. This is associated with a p53-mediated increase in repair of both endogenous and chemotherapy-induced DNA damage. In addition, the inhibition of p38 activities impairs melatonin's capability to induce a p53-dependent DNA damage response and thus its ability to maintain genome integrity. Since melatonin-induced p53 phosphorylation requires an intact p38 phosphorylation cascade and p38 can be activated by G proteins, we supposed that melatonin's activities could be mediated by its G-protein-coupled membrane receptors, MT1 and MT2. Here, we show that the activation of the p53-dependent DNA damage response by melatonin is indeed mediated by MT1 and MT2. As a result, the absence of either receptor impairs melatonin's ability to reduce both cell proliferation and clonogenic potential of cancer cells. In addition, this causes an impairment of the p53-dependent DNA damage response. By providing molecular insight, our findings might have translational impact, suggesting the involvement of melatonin receptors in tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ATM and related protein kinases: safeguarding genome integrity
Shiloh, Y. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1011 · Cited by 2,577
Enhanced Phosphorylation of p53 by ATM in Response to DNA Damage
Banin, S., Moyal, L., Shieh, S.-Y., Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y., et al. (1998) · Science · doi:10.1126/science.281.5383.1674 · Cited by 1,797
Regulation of p53 in response to DNA damage
Lakin, N. D., & Jackson, S. P. (1999) · Oncogene · doi:10.1038/sj.onc.1203015 · Cited by 987 · cited 1×
“When this occurs, a DNA repair response is induced, in which phosphorylated p53 plays a central role (19,21,44).”
BackgroundMelatonin receptors: role on sleep and circadian rhythm regulation
Dubocovich, M. L. (2007) · Sleep Medicine · doi:10.1016/j.sleep.2007.10.007 · Cited by 364
Hong, Y., Downey, T., Eu, K. W., Koh, P. K., & Cheah, P. Y. (2010) · Clinical & Experimental Metastasis · doi:10.1007/s10585-010-9305-4 · Cited by 319 · cited 1×
“Invasive ductal breast carcinoma (45); 2.”
Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?
Jockers, R., Maurice, P., Boutin, J. A., & Delagrange, P. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.184 · Cited by 293 · cited 1×
“Both MT1 and MT2 are G-protein-coupled membrane receptors which, upon ligand binding, activate G proteins and inhibit cyclic adenosine 3′,5′-monophosphate formation (10,34).”
BackgroundBlask, D. E., Hill, S. M., Dauchy, R. T., Xiang, S., Yuan, L., Duplessis, T., Mao, L., Dauchy, E., & Sauer, L. A. (2011) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00888.x · Cited by 187 · cited 2×
“Invasive ductal and invasive lobular breast carcinoma (11); 3.”
BackgroundUrinary Melatonin Levels and Postmenopausal Breast Cancer Risk in the Nurses' Health Study Cohort
Schernhammer, E. S., & Hankinson, S. E. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0637 · Cited by 123
Kovacs, D., Flori, E., Maresca, V., Ottaviani, M., Aspite, N., Dell'Anna, M. L., Panzella, L., Napolitano, A., Picardo, M., & d'Ischia, M. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.457 · Cited by 50
Cited by
Broad targeting of angiogenesis for cancer prevention and therapy
Wang, Z., Dabrosin, C., Yin, X., Fuster, M. M., Arreola, A., Rathmell, W. K., Generali, D., Nagaraju, G. P., El-Rayes, B., Ribatti, D., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.01.001 · Cited by 464
Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis
Reiter, R., Rosales-Corral, S., Tan, D.-X., Acuna-Castroviejo, D., Qin, L., Yang, S.-F., & Xu, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040843 · Cited by 433
Melatonin: an inhibitor of breast cancer
Hill, S. M., Belancio, V. P., Dauchy, R. T., Xiang, S., Brimer, S., Mao, L., Hauch, A., Lundberg, P. W., Summers, W., Yuan, L., et al. (2015) · Endocrine-Related Cancer · doi:10.1530/erc-15-0030 · Cited by 317
Melatonin receptors: molecular pharmacology and signalling in the context of system bias
Cecon, E., Oishi, A., & Jockers, R. (2018) · British Journal of Pharmacology · doi:10.1111/bph.13950 · Cited by 281
Is Melatonin the Cornucopia of the 21st Century?
Ferlazzo, N., Andolina, G., Cannata, A., Costanzo, M. G., Rizzo, V., Currò, M., Ientile, R., & Caccamo, D. (2020) · Antioxidants · doi:10.3390/antiox9111088 · Cited by 189
“Melatonin acts as an antioxidant on normal cells by enhancing DNA repair enzymes, thus slowing down cell death and toxicity induced by radio and chemotherapy [154]; however, on most cancer cells it exerts a pro-oxidant action stimulating endogenous ROS production with consequent DNA damage and cell death [148].”
Background
Metadata
- Authors
- Santoro, R., Mori, F., Marani, M., Grasso, G., Cambria, M. A., Blandino, G., Muti, P., & Strano, S.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-01-25
- Volume
- 34
- Issue
- 5
- Pages
- 1051-1061
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2097919146
- Cited by
- 62
- References
- 9
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.